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Abstract 
The predominant role of IL-6 in cancer is its key promotion of tumour growth. IL-6 binds IL-6 receptor (IL-6R) and 
the membrane-bound glycoprotein gp130. The complex I-6/IL-6R/gp130 starts the Janus kinases (JAKs) and 
signal transducer and activator of transcription 3 (STAT3) or JAK/STAT3 pathway. IL-6R exits in two forms: a 
membrane-bound IL-6Rα subunit (mIL-6R) that participates in classic signalling pathway and soluble IL-6R 
subunit (sIL-6R) engaged in trans-signalling. The pro-tumour functions of IL-6 are associated with STAT3, a major 
oncogenic transcription factor that triggers up-regulation of target genes responsible for tumour cell survival. IL-6 
combined with TGF-β induces proliferation of pathogenic Th17 cells. The anti-tumour function of IL-6 is the 
promotion of anti-tumour immunity. IL-6 trans-signaling contributed to transmigration of lymphocytes in high 
endothelial venules (HEV). Dendritic cell (DC) secreted IL-6 in the lymph node influences the activation, 
distribution and polarisation of the immune response. Elevated serum levels of IL-6 and increased expression of 
IL-6 in tumour tissue are negative prognostic marker for patients’ survival. 
 
 
 
 
 
 
 
 
 
Introduction 
 
The cytokine interleukin-6 (IL-6) is a member 
of a group of cytokines that possess a four-helical 
structure [1]. It was described first as a B cell 
differentiation factor in 1986 [2], [3], [4]. IL-6 has 
various biological activities such as stimulation of the 
growth of tumour cells of murine plasmacytoma and 
human myeloma [5]. IL-6 also has an inhibitory effect 
on the antiviral antibody response [6]. Moreover, IL-6 
is produced by several types of cells such as 
monocytes, macrophages, Kupffer cells [7], 
keratinocytes, endothelial cells, B cells and T cells [1].  
The intracellular signaling is induced when the 
complex of IL-6 and IL-6 receptor (an 80-kDa ligand-
binding chain IL-6Rα, CD126) binds the membrane 
glycoprotein 130 (gp 130) (a signal-transducing chain, 
IL-6Rb, CD130) [8], [9] that initiates the Janus kinases 
(JAKs) and signal transducer and activator of 
transcription (STAT) or JAKs / STAT pathway [8]. IL-
6R is found in two forms, a transmembrane form mIL-
6Rα, and a soluble form sIL-6R. IL-6 binds to both of 
these forms and subsequently interacts with the gp 
130 to trigger downstream signal transduction and 
gene expression [7]. The gp130 lacks an intrinsic 
kinase domain, and therefore the members of the 
JAKs family, like JAK1, JAK2 and tyrosine kinase 2 
(Tyk2), are linked to gp130 [5]. The complex of IL-6, 
IL-6R and gp130 phosphorylates the afore-mentioned 
kinases and later activates the cytoplasmic 
transcriptional factors as STAT1 and STAT3 [10]. 
Therefore, IL-6 activates transcriptional factors 
through IL-6R/gp130 complexes with following 
downstream effects [5]. 
The membrane-bound IL-6Rα subunit is 
located on the membrane of target cells. The second 
receptor subunit is the gp130 associated with mIL-
6Rα/IL-6 that subsequently activates the “classic 
signaling pathway” [11]. The complex IL-6 / mIL-6Rα 
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leads to dimerisation of gp130 and subsequent 
activation and phosphorylation of STAT3 via JAK. The 
classic signalling is realised during the early immune 
responses and activates acute-phase proteins like C-
reactive protein (CRP) [9]. This “classic signalling” is 
accomplished on cells, expressing both the mIL-6R 
subunit and gp130 subunit. The latter is widely 
expressed, but the former is found only on 
hepatocytes, leukocytes and megakaryocytes [5], [9]. 
The second mechanism of induction of 
intracellular reaction is when IL-6 associates with 
soluble IL-6R (sIL-6R) and binds gp130 on cellular 
membranes that do not express mIL-6Rα. That 
process is defined as “trans-signalling” an alternative 
of classic signalling [12]. The presence of sIL-6R in 
the serum is a result of shedding of the mIL-6R from 
the cellular membranes induced by apoptosis and 
realised through a dis-integrin and a 
metalloproteinase 10 (ADAM10 or ADAM17) [13]. A 
second way of achieving sIL-6R is via differential 
splicing of IL-6 mRNA [12]. The shedding of the IL-6R 
is also initiated by CRP [14,15], or bacterial toxins 
[16]. The shedding of IL-6R is released from 
neutrophils at the beginning of the inflammatory 
process [9]. The presence of sIL-6R and IL-6 induces 
Th17 cells and is responsible for the balance between 
Th17 and T regulatory cells (Tregs) [17]. Therefore, 
IL-6 trans-signaling modulates the T cell response 
[18]. IL-6 trans-signalling is observed in many cell 
types such as epithelial cells, neutrophils, 
macrophages and T cells [9] and that the complex of 
IL-6 with the sIL-6R is associated with the cellular 
membrane gp130 [19] (Figure 1). 
 
Figure 1: IL-6/JAK/STAT3 signaling; A) Classical-signaling: IL-6 
binds to mIL-6 R, and interplays with membrane gp 130; B) Trans-
signaling: sIL-6R cleaved from macrophage membranes binds to IL-
6 and then the complex interplays with membrane gp130; Then the 
complex IL-6 / IL-6R / gp130 triggers the activation of JAK, and 
meanwhile the suppressor of cytokine signalling (SOCS) acts on 
JAKs and stops phosphorylation of gp130, STATs and the JAKs 
themselves. STAT3 (an oncogenic transcriptional factor) is 
activated by JAKs, phosphorylated and formed dimers (pSTAT3-
pSTAT3). The dimerised pSTAT3 complex moves to nucleus and 
pSTAT3 complex trigger transcription of STAT3 target genes (cyclin 
D1, VEGF, c-myc, etc) through interaction with DNA. Cancer 
promotion is initiated. The protein inhibitors of activated STATs 
(PIAS) can suppress the transcription of STAT3 target genes 
 
IL-6 up-regulates several acute-phase 
proteins such as CRP, fibrinogen, etc. [15], and IL-6 
has both anti- and pro-inflammatory activities [9]. The 
anti-inflammatory functions are realized by the 
complex IL-6/mIL-6R and include activation of STAT3, 
followed by intestinal cell proliferation, inhibition of 
epithelial cell apoptosis and release of acute-phase 
proteins [19], [20]. The pro-inflammatory activities are 
realized by the complex IL-6 / sIL-6R and include 
activation of the immune system through recruitment 
of mononuclear cells (myeloid-derived suppressor 
cells – MDSC and macrophages), inhibition of T cell 
apoptosis and down-regulation of Treg differentiation 
[17], [21] (Figure 2). 
 
Figure 2: The dual role of IL-6 signalling: IL-6 classical signalling 
with anti-inflammatory properties and IL-6 trans-signalling with pro-
inflammatory properties 
 
During chronic inflammation, IL-6 induces 
proliferation of Th17 cells and inhibits the 
differentiation of Tregs [11]. The predominant cell type 
that secreted IL-6 during acute inflammation is 
monocyte/macrophage and in chronic inflammation – 
T lymphocyte [22]. IL-6 is also produced by 
endothelial cells, B cells, T cells, fibroblasts and some 
tumour cells [1]. IL-6 can be secreted by stromal 
fibroblasts in a mouse model of gastric cancer [23]. 
Colon tumours usually have a decreased 
expression of membrane-bound IL-6R in comparison 
to normal epithelial colon tissue. Nevertheless, the 
expression of ADAM17, associated with shedding of 
the IL-6R, is increased in tumours, and therefore the 
“trans-signalling” pathway is involved in colon 
carcinogenesis [24], [25]. 
 
 
Interleukin-6 and cancer development 
 
Pro-tumour functions of IL-6 
The predominant role of IL-6 in cancer is the 
promotion of tumour growth. The interaction of IL-6 
and its receptor-activated JAKs with following 
induction/activation of STAT3 through tyrosine 
phosphorylation and subsequent transcription of 
target genes [9] is vital in cancer formation. In turn, IL-
6 induces IL-6-dependent STAT3 activation, resulting 
in up-regulation of genes that promote the survival of 
cancer cells [26]. The target genes responsible for 
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tumor cell survival (Bcl-2, survivin, Mcl-1), [27] 
proliferation (c-Myc, Cyclin D1, Cyclin B) [28], 
angiogenesis (VEGF) [29], metastasis (MMP2, 
MMP9) [30], [31], cell adhesion (ICAM-1, TWIST1), 
inflammation (IL-6, IL-17, IL-23, Cox2), and others 
[32]are influenced by IL-6 activities. 
STAT3 is a major oncogenic transcription 
factor that is activated by the binding of IL-6 to the IL-
6 receptor [25]. The first event is the binding of IL-6 to 
mIL-6R followed by gp130 dimerisation and trans-
phosphorylation of STAT3 through tyrosine 
phosphorylation. Subsequently, STAT3 trans-locates 
to the nucleus in epithelial tumour cells, where STAT3 
dimers bind DNA and modulate the expression of 
some target genes [22], [33]. Additionally, the IL-6 / 
STAT3 pathway blocks the maturation of dendritic 
cells (DCs), inhibits T cell activation [34] and 
maintains immunosuppression through MDSC and 
macrophages (tumour-associated macrophages – 
TAMs) [35]. 
IL-6 is also involved in the differentiation of 
monocytes to macrophages, downregulates apoptosis 
of T lymphocytes, and the production of Th2 cytokines 
[3], [36], [37]. 
 
Figure 3: IL-6 and IL-27 trigger a common signal transduction 
pathway in T cell 
 
Several molecules secreted by tumour cells, 
including IL-1β, TNF-α, IL-6 and TGF-β are 
considered to be promoters of Th17 differentiation 
from naïve CD4+ T cells. There exists evidence that 
Th17 cells increase in number in the tumour 
microenvironment (TME) [38]. In contrast, IFN-γ and 
IL-4, the main cytokines involved in Th1 and Th2 
polarisation, respectively, negatively regulate Th17 
differentiation [25], [38]. The pro-inflammatory 
cytokines, IL-6 and TNF-α, are produced in TME 
mostly by hematopoietic cells and also by tumour 
cells. They are tumour-promoting and further enhance 
nuclear factor kappa B (NF-kB) and STAT3 activation 
[39,40]. Moreover, IL-6 and IL-27 mediate signal 
transduction through STAT3 and STAT1 activation of 
Th17 and Treg differentiation [48]. IL-6 combined with 
TGF-β3 or TGF-β1 induce proliferation of pathogenic 
Th17 cells [42]. IL-6 and IL-27 both can initiate 
common signal transduction pathways in T cells [41] 
(Figure 3). 
STAT3 is an essential activator for Th17 cell 
proliferation [43], and on the other hand IL-6, a STAT3 
activator, together with TGF-β increased the 
expression of main transcription factors RORα 
(human) and RORγt (mouse) for Th17 cell induction 
and IL-17 production [44], [45]. In contrast to STAT3 
activation, STAT1 activation inhibits the development 
of Th17 cells [46]. Cytokines like IL-27 and IFN-γ are 
involved in the inhibition of Th17 development in a 
STAT1-dependent manner [5], [46]. Another cytokine 
that inhibits Th17 cells development is IL-2 in a 
STAT5 manner [47]. Therefore, the STAT family 
transcription factors, via the action of various 
cytokines, exert positive or negative influences on 
Th17 development. Interferon-regulatory factor 4 (IRF-
4) exerts positive effect on Th17 cell appearance [48] 
and T-bet negatively influence the development of 
Th17 cells [49]. Treg helpers are mainly naturally 
occurring thymus-derived Tregs (nTregs) and TGF-β-
induced Tregs (iTregs) [17]. Also, iTregs generate 
from naïve T cells in the periphery, after stimulation 
with TGF-β [50]. There are other T cells with 
regulatory functions including the CD8+ Tregs, Tr1 
cells, and Th3 cells [51]. The balance between Th17 
cells and Tregs is controlled by IL-6 that maintains 
immune homeostasis. TGF-β is important for Th17 
and Treg cells differentiation, and it induces both 
Foxp3 and RORγt expression [52]. Therefore, IL-6 is 
considered to be a pro-inflammatory cytokine that 
promoted Th17 cell differentiation and inhibits Tregs 
development. The cytokine IL-17 has dual roles in 
TME, having pro- and anti-tumour activities [53] 
(Figure 4). 
 
Figure 4: IL-6 maintains Th17/Treg balance. IL-6, together with 
TGF-β triggers Th17 differentiation from naïve T cells. On the other 
hand, IL-6 alone inhibits Treg differentiation triggered by TGF-β 
itself 
 
IL-6 is a growth factor for human colon cancer 
cells, and inhibition of IL-6 signalling interferes with 
the growth of tumour cells [24]. In TME tumour-
infiltrating lymphocytes (TILs) produce elevated levels 
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of pro-tumorigenic cytokines such as IL-17A, IL-17F, 
IL-21, IL-22, TNF-α and IL-6 [40]. Some of the 
cytokines like IL-6 and TNF-α are also produced by 
tumour cells [20]. Colorectal cancer (CRC) cell lines - 
DLD-1 and HT-29, are affected by IL-6, TNF-α and IL-
17 cytokines, and result in enhanced NF-kB and 
STAT3, which induce colorectal cancer cell growth 
[40]. 
IL-6 plays a major role in promoting 
proliferation of tumour cells and in inhibiting apoptosis 
via binding to IL-6Rα to the gp130. Following 
activation of JAK / STAT signalling pathway [54] 
namely of STAT1 and STAT3 [55] cancer initiation 
and proliferation occurs. Similarly, to TNF-α, IL-6 
supports tumour development by induction of normal 
epithelial cells to convert into cancer stem-like cells 
[56]. STAT3 can mediate nuclear translocation of β-
catenin. The nuclear co-expression of pSTAT3 and β-
catenin is associated with poor survival of colon 
cancer patients [57]. IL-6 initiates tumorigenesis by 
hypermethylation of tumour suppressor genes or by 
hypomethylation of retrotransposon long interspersed 
nuclear element-1 (LINE-1) in oral squamous cell 
cancer [58]. IL-6 is a powerful (relevant) angiogenic 
factor, and its high levels correlate with that of VEGF 
in colorectal cancer [59,60]. Moreover, IL-6 initiates 
VEGF action in gastric cancer [61]. The secretion of 
IL-6 and subsequent STAT3 phosphorylation up-
regulate some angiogenic mediators such as VEGF, 
VEGFR2 and neuropilin 2 [62]. 
 In conclusion, IL-6 in the TME supports 
tumour development, metastasis and evasion from the 
effective anti-tumour immune response.  
 
Anti-tumour functions of IL-6 
The main anti-tumour function of IL-6 is the 
promotion of anti-tumour immunity [63], [64]. The 
analysis of many specimens of human tumours 
reveals that the immune contexture, defined by the 
type of immune cells, their activity, and distribution 
mainly in the invasive front, is a better prognostic 
factor as compared to histological staging and grading 
[63]. There is evidence that IL-6 trans-signalling is 
important in the initiation of T cell immune responses 
[65], [66]. Using trans-signalling IL-6 is a key cytokine 
in the modulation of anti-tumor immune response [67]. 
IL-6 maintains anti-tumour immunity at two main sites: 
first in the lymph nodes where lymphocyte priming 
takes place and second in tumour nests where IL-6 
promotes the recruitment of effector T cells in TME 
[68]. 
In lymph nodes, dendritic cells (DCs) 
encounter tumour antigens. Also, naïve T cells and 
memory T cells enter lymph nodes through high 
endothelial venules (HEV). The polarisation interacts 
with the naïve T cells and initiates T cell polarisation 
[69], [70]. DCs secrete IL-6 in the lymph node that 
influences the activation, distribution and polarisation 
of the immune response [71]. 
In HEV, IL-6 trans-signaling acts on T 
lymphocytes to initiate tethering and rolling on the 
endothelial surface of HEV. Later the interaction 
between CCL21 on endothelial cells and CCR7 
chemokine receptor on T lymphocytes initiates the 
chemokine activation that helps firm adhesion. The 
lymphocyte firm adhesion molecule 1 (LFA-1) binds to 
intercellular adhesion molecule 1 or 2 (ICAM-1 or 
ICAM-2) on endothelial cells and lymphocyte trans-
endothelial migration in HEVs in lymph nodes or the 
tumour site [70], [72], [73]. IL-6 trans-signaling 
contributes to L-selectin-mediated and transmigration 
of lymphocytes to HEV [74]. Usually, tumour vessels 
had tortuous structure and express low levels of 
trafficking molecules such as ICAM-[66], [67]. 
Endothelial cells of tumour vessels and cancer-
associated fibroblasts are the main producers of IL-6 
at tumour sites [74]. Thus, injection of H-IL-6 induces 
high IL-6/sIL-6Rα concentration in TME. IL-6 trans-
signaling increases CD8+ T cells trafficking into 
tumours and supports adoptive T cell transfer in 
adoptive cell therapy [67]. In mouse models the 
administration of H-IL-6 or application of systemic 
thermal therapy before adoptive CD8+ T cell transfer 
leads to enhanced tumour cell apoptosis and delay of 
tumour cell growth [67], [74]. 
 The anti-tumour activities of IL-6 trans-
signalling are used as basis for anti-tumour therapy. 
Thermal therapy is based on enhanced lymphocyte 
recruitment as response to febrile temperatures about 
39.50 for periods up to 6 hours [66], [75]. The thermal 
stress leads to transient decrease in lymphocyte count 
with following increase of it in cancer patients with 
subsequent tumour restriction [76], [77]. 
Thermal therapy up-regulates gp130 on the 
endothelial cells in tumour microvessels [78] and thus 
supports IL-6/sIL-6Rα activity with following CD8+ T 
cell trafficking and recruitment into the tumour site 
[74], [78]. Taken together, the administration of H-IL-6 
or thermal therapy could restrain cancer development 
when combined with adoptive CD8+ T cell vaccination 
[67], [78], [79].  
 
Elevated levels of IL-6 and other serum 
 biomarkers in cancer patients  
Various biomarkers for the initiation and 
development of cancer exist. These biomarkers are 
associated mainly with inflammation and obesity [15], 
[80]. Chronic inflammation is related to colon 
carcinogenesis [68], [81]. It has been reported that 
cancer-associated inflammation determined disease 
progression and survival in CRC [82]. 
The existing meta-analysis shows that serum 
CRP and IL-6 levels could be associated with the risk 
of CRC development [33], [83], [84] but this is not 
useful for identifying colorectal adenomas [85]. TNF-α 
serum levels were studied in the risk of CRC 
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development [86]. Another investigation report 
increased mRNA level of IL-6 that is predictive for 
colorectal cancer development with distant 
metastases [87]. Several CRC case-control studies 
show increased serum levels of CRP, TNF-α, IL-6 and 
IL-8 in colorectal adenoma and CRC patients [88]. 
Moreover, expression-enhancing polymer-phisms in 
the genes for IL-6, TNF-α, IL-1β and IL-8 are 
associated with increased risk for the development of 
colorectal cancer [89]. The increased release of IL-6 
in the sera of CRC patients is associated with CEA-
induced production of IL-6 by Kupffer cells, 
macrophages, lymphocytes and tumour cells [90]. 
Serum IL-6 > 10 pg/ml values are associated with 
higher incidence of CRC with distant metastasis and 
therefore can be an independent, negative prognostic 
marker for patients’ survival [91].  
Adipose tissue is considered to be the largest 
endocrine tissue that secrets various cytokines such 
as IL-2, IL-6, IL-8, TNF-α, etc. [92]. IL-6 is a poor 
prognostic factor in obese patients with CRC [93], 
[94], [95], [96].  
 
Clinical significance of tissue 
 overexpression of IL-6 in CRC cancer 
 tissue 
Few studies address the immunohisto-
chemical expression of IL-6 in CRC [97], [98], [99]. 
Some studies show overexpression of IL-6 in tumour 
tissue in glioblastoma [94], prostate cancer [43], renal 
cell cancer [57], gastric cancer [61] etc. Additionally, 
the expression of IL-6R and gp130 was investigated in 
tumour cells of CRC [97]. The overexpression of IL-6 
in cancer tissue correlates to advanced stage, lymph 
node metastasis, and venous invasion [100], [101]. 
Therefore, IL-6 cancer cell expression can be a 
relevant marker of cancer progression. 
In conclusion, IL-6 is mainly a pro-tumorigenic 
cytokine that triggers JAK / STAT3 activation with 
subsequent promotion of tumour cell growth and 
suppression of tumour cell apoptosis. IL-6 / STAT3 
signalling regulates the balance between Th17 and 
Tregs in TME with immunosuppressive properties. 
The anti-tumour activity of IL-6is associated with 
modulation of T cell polarisation initiated by IL-6 
secreting DCs and with the support of T lymphocyte 
recruitment in lymph nodes. A further investigation is 
necessary to elucidate the intimate mechanisms of IL-
6 regulation. 
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